UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities:
Net income	$ 30,923	$ 81,970
Adjustments to reconcile net income to cash provided by operating activities:
Gain on sale of discontinued operations	0	(64,619)
Deferred income tax provision, net	874	1,428
Provision for bad debts on accounts receivable	1,861	1,080
Depreciation and amortization	7,411	7,541
Stock-based compensation expense	4,261	2,084
Pension and post-retirement benefit plans expense	1,395	990
Amortization of deferred financing costs	90	79
Excess tax benefit attributable to stock-based compensation	(408)	(128)
Loss on deferred compensation plan investments, net	192	195
Gain from Company-owned life insurance proceeds	0	(849)
Contingent consideration liability remeasurement	524	0
Other	172	(186)
(Increase) decrease in operating assets
Trade receivables, net	(13,229)	(38,303)
Income tax refund receivable	1,097	7,681
Prepaid expenses and other current assets	496	66
Other assets, net	(322)	(42)
Increase (decrease) in operating liabilities
Accounts payable and other current liabilities	1,872	4,854
Accrued payroll costs	12,067	6,674
Income taxes payable	3,129	(4,671)
Other long-term liabilities	2,751	(2,135)
Cash provided by operating activities	55,156	3,709
Cash flows from investing activities:
Proceeds from disposition of business	0	117,887
Capital expenditures	(7,731)	(4,787)
Proceeds from the disposition of assets held within the Rabbi Trust	445	2,330
Purchase of assets held within the Rabbi Trust	(481)	(2,156)
Proceeds from Company-owned life insurance	0	1,037
Other	0	1
Cash (used in) provided by investing activities	(7,767)	114,312
Cash flows from financing activities:
Proceeds from bank line of credit	443,195	444,846
Payments on bank line of credit	(455,635)	(494,778)
Payments of capital expenditure financing	(956)	(878)
Short-term vendor financing	(630)	146
Proceeds from exercise of stock options, net of shares tendered in payment of exercise	381	949
Excess tax benefit attributable to stock-based compensation	408	128
Payment of loan financing fees	0	(35)
Repurchases of common stock	(24,883)	(58,550)
Cash dividend	(9,261)	(9,607)
Cash used in financing activities	(47,381)	(117,779)
Change in cash and cash equivalents	8	242
Cash and cash equivalents at beginning of period	1,238	875
Cash and cash equivalents at end of period	$ 1,246	$ 1,117